A German Study - Metastatic Breast Cancer: Experience with the Combination Paclitaxel Plus Epirubicin

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 36-39

  Lück, Hans Joachim ^a   Thomssen, Christopher ^b   Du Bois, Andreas ^c   Untch, Michael ^d   Lisboa, Björn ^e   Kohler, Günther ^f   Diergarten, Klaus ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c St Vincentius Krankenh   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF GREIFSWALD   (Germany)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARDIOTOXICITY; COHORT ANALYSIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 0031941353     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Holmes FA, Walters RS, Theriault RC, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
2. Reichman BS, Seidman AD, et al: Paclitaxel and recombinant granulocyte-stimulating factor as initial chemotherapy for metastatic breast cancer. Semin Oncol 11:1943-1951, 1993.
3. Holmes FA, Frye D, et al. Phase I study of Taxol and doxorubicin for metastatic breast cancer. Proc Am Soc Clin Oncol 11:60, 1992.
4. Sledge GW Jr, Robert N, et al. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21.15-18, 1994.
5. Dombernowski P, Gehl J, Ejlersen B, et al: Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Emerging Strategies in Medical Oncology 3-4, 1994
6. 6a. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose finding and sequence finding study. J Clin Oncol 13:2688-2699, 1995.
7. 6b. Gianni L, Capri G, Tarenzi E, et al: Efficacy and cardiac effects of 3-h paclitaxel plus bolus doxorubicin in women with untreated metastatic breast cancer (abstract 128). Proc Am Soc Clin Oncol 15:116, 1996.
8. 6c. Moliterni A, Tarenzi E, Capri G, et al: Pilot study of primary CT with doxorubicin plus paclitaxel in women with locally advanced breast cancer or operable breast cancer Semin Oncol 24(suppl 17).10-14, 1997.
9. Praga C, Trave F, Petroccion A: Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. Clinical Measurements in Drug Evaluation 131-142, 1991.
10. Brambilla C, Ross A, Bonfonte V, et al: Phase II study of doxorubicin vs epirubicin in advanced breast cancer. Cancer Treat Rep 70:261-266, 1986
11. Lawton PA, Ostrowski M, Young T. Efficacy and toxicity of single-agent chemotherapy in advanced breast cancer. Br J Cancer 61:177, 1990.
12. Pervodchikova NI, Valvore VJ: Comparative evaluation of farmorubicin and Adriamycin in breast cancer. Progress in Antimicrobial and Anticancer Chemotherapy 3: 474-477, 1997.
13. Hortobagyi GN: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12: 57-62, 1989.
14. Jain K, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer J Clin Oncol 3 818-826, 1985.
15. Taguchi T, Ogawa M, Izuo M, et al. A prospective randomized trial comparing epirubicin and doxorubicin in advanced breast cancer. J Cancer Chemother 13: 3498-3507, 1986.
16. Van Oosterom AT, Andersson M, et al Adriamycin (A) versus 4-epi-adriamycin (E) Report of a second-line randomised phase III study in advanced breast cancer (trial 10811). Proceedings of the IV EORTC Breast Cancer Working Conference 1.6:1987.
17. Perez DJ, Harvey VJ, Robinson BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991.
18. Mouridsen HT, Alfan C, et al. Current status of epirubicin (farmorubicin) in the treatment of solid tumors. Acta Oncol 29 257-285, 1990